Objective: In addition to the main multiple sclerosis (MS) major histocompatibility complex (MHC) risk allele (HLA DRB1*1501), investigations of the MHC have implicated several class I MHC loci (HLA A, HLA B, and HLA C) as potential independent MS susceptibility loci. Here, we evaluate the role of 3 putative protective alleles in MS: HLA A*02, HLA B*44, and HLA C*05.
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS that has a component of genetic susceptibility. The locus with the strongest association with susceptibility is the major histocompatibility complex (MHC), and this association has been well-validated in a multitude of studies. 1 The main risk haplotype for MS within the MHC is tagged by the HLA DRB1*1501 allele. 1 However, there is mounting evidence that other haplotypes may also contribute to MS susceptibility in European populations. [2] [3] [4] [5] In particular, 3 class I MHC alleles have been proposed to be associated with susceptibility to MS after accounting for the effect of HLA DRB1*1501: HLA A*02, HLA B*4402, and HLA C*05. 2, [6] [7] [8] [9] [10] The most recent class I MHC allele, HLA B*4402, was discovered by imputing HLA alleles from single nucleotide polymorphism (SNP) genotype data and is consistent with a recent report that the HLA Bw4 group of HLA B alleles (which includes HLA B4402) is associated with reduced susceptibility to MS. 8, 11 While imputation of SNP data provides good estimates of HLA type in many cases, the effectiveness of this method is allelespecific. SNP data can localize an effect, but there is, as yet, not a comprehensive set of surrogate SNPs for each MHC class I or II allele. 12 Thus, we turned to a novel, independent dataset of class I and II MHC typing data to validate the respective roles of these 3 MHC class I alleles. Our new data are of 2-digit resolution, meaning that, for example, HLA B*4402 is one of several alleles captured under the HLA B*44 rubric used in the HLA typing data that we have collected in the subjects from the Partners MS Center in Boston.
Here, we replicate the existence of HLA DRB1*1501-independent MHC class I susceptibility haplotypes and refine the relative roles of HLA A*02, HLA B*44, and HLA C*05. While the HLA C*05 allele appears to be secondary to HLA B*44, HLA A*02 is an independent risk allele. Secondarily, we extend our analysis to explore the phenotypic associations of the protective HLA A*02 and HLA B*44 alleles in subjects with MS.
METHODS Human subjects. All subjects with MS met the revised McDonald diagnostic criteria 13 or had a clinically isolated demyelinating syndrome (CIS); the latter subjects have a history of a single episode of inflammatory demyelination documented by a neurologist and had 2 or more periventricular or ovoid hyperintense T2 lesions of Ͼ3 mm on MRI. 14 The control subjects consist of a population of 776 anonymous samples from unrelated subjects consecutively recruited as volunteer donors for a bone marrow registry by the C.W. Bill Young Department of Defense Marrow Donor Program. Because of the recruitment setting, individuals are unlikely to be related and are likely to originate from different areas of the United States. The MS and control subjects are self-identified as non-Latino, non-Asian, non-African American subjects of European ancestry. The demographic profile of both sets of subjects is outlined in table 1.
Standard protocol approvals, registrations, and patient consents. The study was approved by the institutional review board of Partners Healthcare and written informed consent was obtained from all patients participating in the study.
Clinical and HLA typing data. Clinical data were obtained from the Partners MS Center Oracle relational database. At each clinic visit, the Expanded Disability Status Scale (EDSS) score is measured on each patient. 15 Using the EDSS and disease duration recorded at the most recent clinic visit, the Multiple Sclerosis Severity Score (MSSS) of each subject was calculated using the Global MSSS table provided by Roxburgh and colleagues. 16 A total of 374 patients had an EDSS and recorded disease duration of 30 years or less and contributed to the MSSS analysis. Details on the generation of the HLA typing data are available in appendix e-1 on the Neurology ® Web site at www.neurology.org. 17, 18 Radiographic data. The details of the Partners MS Center's collection of volumetric data have been previously described. 19 In short, routine clinical MRI scans were obtained on a 1.5-Tesla magnetic resonance system (Signa, GE Medical Systems, Milwaukee, WI) using a standard birdcage quadrature coil as part of routine clinical practice at the Partners MS Center. 20 Each brain is segmented using an automated template-driven segmentation pipeline termed TDSϩ. 21, 22 No healthy control subjects had radiographic data. A total of 378 patients (2,067 scans) with MHC class I information had radiographic data and recorded disease duration less than 40 years. A detailed description of our data extraction and quality control pipeline is available in appendix e-1. The final dataset consisted of 375 patients with 1,933 scans.
Statistical analysis. The allele frequencies for HLA DRB1*1501, HLA A*02, HLA B*44, and HLA C*05 were calculated by tabulating the total number of alleles of each category. Genetic association was assessed using a standard 2 test completed on a 2 ϫ 2 contingency table for each HLA allele tested. The association between other alleles at each loci was also considered using the same approach. In order to address the potential for association due solely to linkage disequilibrium, multiple logistic regression models were used to estimate the association between HLA A*02, HLA B*44, and HLA C*05 and susceptibility controlling for HLA DRB1*1501 and the other loci. In each case, the number of alleles was used as the predictor in the model. Interactions between alleles on the log odds scale were investigated using the logistic regression model. In addition, the association between the secondary loci and susceptibility was investigated in HLA DRB1*1501Ϫ/Ϫ patients. For comparison of clinical characteristics in the patients with MS, a Kruskal-Wallis test was used to compare the MSSS across the 3 genotype groups. For comparison of age at onset and radiographic characteristics (brain parenchymal fraction [BPF] and log-transformed T2 lesion volume), we compared the characteristics at last visit using linear regression with an additive effect of each allele. Multivariate models for the radiographic characteristics were also investigated to control for age, disease duration, and gender. For longitudinal MRI follow-up, the change over time in BPF and T2 lesion volume was investigated using a random intercept and slope model. For this approach, an additive effect of each allele was used as a predictor. To assess whether an allele had a significant effect on the change with time, the interaction between the allele and study time was investigated. The model also included . Given our data, these alleles were not included in further modeling, and we focused on the class I alleles since they displayed much more robust evidence of association. No other DRB1 alleles were considered in the modeling since HLA A*02 and HLA B*44 were the first and second most associated allele among the tested loci after the effect of HLA DRB1*1501 was taken into account. To address whether the 3 HLA alleles of interest have independent effects, multiple logistic regression was used. After accounting for the effect of HLA DRB1*1501, all 3 alleles remained associated with MS susceptibility (table 3) . Given this residual association, a set of additional regression analyses examined the effect of each of the three alleles in the presence of the other alleles (table 3) . This series of analyses demonstrated that the effect of the HLA C*05 allele was secondary to that of the HLA B*44 allele and HLA A*02 allele since no significant residual association was observed with HLA C*05 in the larger models. No significant gene/gene interactions were observed in these analyses. This confirms our earlier analysis that suggested the secondary role of HLA C*05 relative to HLA B*44 using SNP data in a different sample set. 8 These analyses also examined the relative roles of the HLA A*02 and HLA B*44 alleles in the presence of the other allele. In our dataset, these 2 associations appeared to be distinct since a residual association with MS susceptibility remained for (1) HLA A*02 in the presence of HLA DRB1*1501 and HLA B*44 and (2) HLA B*44 in the presence of HLA DRB1*1501 and HLA A*02 (table 3) . No significant gene/gene interaction between HLA B*44 and HLA A*02 was observed in this analysis. Thus, our study suggests the existence of 2 separate MHC class I associations, confirming both the recent report concerning HLA B*44 and the published associations with HLA A*02.
To confirm these results using a different approach, we also analyzed our data after limiting the analysis to those subjects who were HLA DRB1*1501Ϫ/Ϫ. Table e-3 reports the results of these analyses, which mirror the results of the primary analysis. In particular, HLA A*02 and HLA B*44 had independent effects while HLA C*05 appeared to be have no residual effect in the presence of HLA B*44.
Given the existence of 2 MHC class I loci associated with MS susceptibility, the association between these loci and MS outcomes was examined. In our cross-sectional analyses, HLA A*02 did not have a significant association with either our clinical measures-the age at symptom onset and MSSS-or measures derived from MRI-BPF and T2 hyperintense lesion volume at last visit (table 4) . On the other hand, HLA B*44 was associated with both MRI measures at last visit in both univariate ( p ϭ A comprehensive assessment of evidence of association between HLA A, B, C, and DRB1 alleles and MS susceptibility is provided in tables e-1 and e-2. Consistent with previous reports, the relatively uncommon HLA DRB1*14 allele displayed modest evidence of a protective effect in terms of MS susceptibility. 3, 23 In addition, there is evidence of further heterogeneity in the MHC locus, with 3 sugges-tive associations appearing in the analysis where the effects of HLA A*02, HLA B*44, and HLA DRB1*1501 are accounted for (full model p) (tables e-1 and e-2): HLA A*03, univariate (no covariates) p ϭ 0.8, full model p ϭ 0.001; HLA C*03, univariate p ϭ 0.0002, full model p ϭ 0.002; and HLA DRB1*11, univariate p ϭ 0.06, full model p ϭ 0.003. Given the 50 alleles tested in this secondary analysis, study-wide significance is established as a full model p Ͻ 0.001. Of note, we saw a nonsignificant trend for a higher frequency of an HLA DRB1*1501/*08 genotype in subjects with MS (data not shown); this genotype combination has previously been proposed as a high-risk genotype in relation to MS susceptibility. 3 
DISCUSSION
In our focused analysis of the MHC class I region, we confirm that this chromosomal segment is associated with MS independently of the HLA DRB1*1501 association. Specifically, we validate for the first time the earlier observation concerning the role of the HLA B*44 allele and confirm the role of the HLA A*02 allele first identified in Scandinavian populations by demonstrating their association with MS susceptibility in an independent cohort of subjects with MS from the Partners MS Center.
The results are consistent with other reports validating the role of the HLA A*02 allele and implicating the HLA Bw4 group of alleles. 7, 9, 11, 24 Further, we enhance the state of the field by demonstrating that these 2 effects are independent of one another and that the previously described association of the HLA Cw*05 allele with susceptibility to MS 2 is likely to be due to linkage disequilibrium with HLA B*44.
In our dataset, both HLA A*02 and HLA B*44 have substantial effects on susceptibility (OR A*02 ϭ 0.67 and OR B*44 ϭ 0.62). These effects are larger than that of the non-MHC risk alleles discovered to date 25 and will play an important role as we assemble a comprehensive map of the genetic architecture of MS in coming years. Given the MHC's allelic heterogeneity, long-range linkage disequilibrium, and the large effect size of HLA DRB1*1501, it is not surprising that loci with effects of this magnitude are only being validated now. In fact, we suspect that additional susceptibility loci will be found within the MHC as part of future investigations in larger sample sets. While the 2 MHC class I alleles discussed here are clearly associated with susceptibility to MS, we should remember that they exist on haplotypes that extend over long physical distances and encompass many different polymorphisms. Thus, we cannot say that HLA A*02 and HLA B*44 are causal variants at this time; they simply represent the best markers of independent protective haplotypes within the MHC. It is also possible that multiple alleles in strong linkage disequilibrium with either allele could be required to achieve the protective effects that we have validated.
The association of MHC class I alleles with susceptibility to MS highlights the role of certain cell types, such as CD8ϩ and natural killer (NK) cells, in the onset of MS. These cell types harbor receptors for MHC class I, and these findings fit well with the reported dysfunction of CD8ϩ and NK cells in early stages of demyelinating disease. 26 Recently, in a largescale scan of peripheral blood cell populations, we identified and validated a reduction in the frequency of a CD56ϩ NK cell population in untreated subjects who either had relapsing-remitting MS or a clinically isolated demyelinating syndrome. 27 Many other investigators have assessed the role of NK cells in MS, and, while some early studies were negative, the preponderance of the evidence available to date suggests that NK cell frequency is reduced in MS and that they may be dysfunctional. 28 The convergence of these immunologic and genetic data strongly argue for a comprehensive assessment of the complex interactions between MHC class I molecules and their various receptors in subjects with MS, both at the genetic and functional level. An early effort in this direction used HLA Bw4 and explored the role of killer immunoglobulin receptors (KIR) in MS susceptibility, including KIR3DL1, which is a receptor for this group of HLA B alleles. 11 While KIR alleles did not appear to be associated in this study of moderate size, modest effects typical of inflammatory disease susceptibility alleles cannot yet be excluded and will require the careful assessment of allele combinations between KIR and MHC class I alleles.
Interestingly, a protective effect of HLA B*44 has been previously reported in subjects with CD95/ TNFRSF6 mutations resulting in autoimmune lymphoproliferative syndrome type 1a. Subjects with such mutations who also bear an HLA B*44 allele were less likely to develop the full spectrum of autoimmune lymphoproliferative syndrome clinical features such as lymphadenopathy, splenomegaly, autoimmunity, and lymphoma. 29 Furthermore, HLA B*44 homozygotes have also been reported to have lower NK cell activity, offering one suggestion as to the mechanism by which HLA B*44 may reduce MS susceptibility. 30 While HLA A*02 and HLA B*44 are clearly validated as protective haplotypes in this and other studies, 9, 11, 24 we see evidence that only the HLA B*44 haplotype affects volumetric MRI measures (BPF and T2 hyperintense lesion volume): on average, subjects with MS with HLA B*44 alleles had a larger brain volume and a lower lesion burden than subjects with MS who lacked this allele. Our secondary analysis of longitudinal data suggests that these correlations may arise from a reduction in the rates of brain atrophy and T2 lesion volume accumulation. Thus, the difference in brain volume at a subject's last MRI is less likely to be due to differences in baseline brain volume. However, further work is needed to confirm our observations relating these MS outcome measures and HLA B*44 as well as an independent report of associations between HLA A*02 and measures of MS disease course that we did not validate in our sample set. 31 Overall, MS susceptibility alleles appear to have a limited role in MS disease severity so far, [32] [33] [34] [35] and dedicated studies are needed to explore the genetic architecture of disease course in MS.
As suggested by our comprehensive assessment of MHC alleles in table e-1, additional risk-associated and protective alleles, particularly in the HLA C locus, may well exist, and dedicated efforts to further explore this critical region are therefore warranted. Such efforts that include-high resolution HLA typing of multiple loci are needed to supplement the ongoing large SNP-based efforts: so far, HLA types are, for the most part, imperfectly tagged by SNP markers and will be needed to identify the causal allele or alleles in each locus.
